Selecta Biosciences (SELB) Earns News Impact Rating of 0.11
News headlines about Selecta Biosciences (NASDAQ:SELB) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.4911455720518 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Selecta Biosciences (NASDAQ SELB) traded down $0.17 during trading hours on Friday, hitting $9.90. 95,814 shares of the stock traded hands, compared to its average volume of 250,538. Selecta Biosciences has a one year low of $8.70 and a one year high of $24.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48. The company has a market cap of $214.85 and a P/E ratio of -3.19.
Several research firms have recently issued reports on SELB. Zacks Investment Research upgraded shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Saturday, November 11th. UBS Group downgraded shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Canaccord Genuity restated a “buy” rating and set a $30.00 price objective on shares of Selecta Biosciences in a report on Tuesday, November 7th. Finally, ValuEngine downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Selecta Biosciences presently has a consensus rating of “Hold” and an average target price of $23.50.
In related news, Director Amir Nashat sold 70,226 shares of the company’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $18.91, for a total value of $1,327,973.66. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Werner Cautreels bought 20,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average cost of $9.31 per share, for a total transaction of $186,200.00. Following the purchase, the insider now owns 321,203 shares of the company’s stock, valued at $2,990,399.93. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 90,098 shares of company stock worth $843,933. Insiders own 41.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/12/24/selecta-biosciences-selb-earns-news-impact-rating-of-0-11.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.